Brought to you by 
Jiangsu Hengrui Medicine Co., Ltd.
https://www.hrs.com.cn/index.html
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Jiangsu Hengrui Medicine Co., Ltd.
New China Indications For Merck, Novo, Boehringer Drugs
China continues with a post-coronavirus approvals rush, granting additional indications to Merck's Keytruda, BI's Ofev and Novo Nordisk's Norditropin.
New China Approvals Include Amgen, Sanofi, Hengrui Drugs, Innovent Biosimilar
Several high-profile products including Dupixent gain approvals in China.
Volume-Based Purchasing Looms Larger In Post-Coronavirus China
China's centralized procurement scheme, if further expanded after causing the prices of 32 drugs to be cut by more than half in the latest round, will leave companies no room to breathe easy amid the already devastating coronavirus outbreak, analysts say.
Hengrui Quickly Fills Celgene Void Amid Nationalism Surge In China
China insists there is no double standard and won’t tolerate any quality issues in its centralized procurement process.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Radiopharmaceuticals, Contrast Agents
-
Biotechnology
- Large Molecule